Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glutamate ionotropic receptor AMPA type subunit 4 (GluA4; encoded by the GRIA4 gene) is a protein subunit of the AMPA receptor, a ligand-gated ion channel mediating the majority of fast excitatory synaptic transmission in the central nervous system[1][3][7][9]. The AMPA receptor is a tetramer composed of GluA1-4 subunits (encoded by GRIA1-4), and it is primarily permeable to sodium and (in some subunit combinations) calcium ions upon binding glutamate[3][1]. GluA4 is involved in synaptic plasticity, including long-term potentiation, and plays an essential role in normal CNS development, learning, and memory[1][4][3]. Dysregulation or mutation of GRIA4 is associated with neurodevelopmental disorders, intellectual disability, and possibly schizophrenia[1][7]. Drugs targeting AMPA receptors (such as perampanel) are used clinically as anticonvulsants and are in experimental use for various neurologic and psychiatric conditions.
Antagonism of the AMPA receptor blocks the fast excitatory synaptic transmission mediated by glutamate; Inhibition of ion channel activity (inhibits sodium and calcium influx)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate ionotropic receptor AMPA type subunit 4 (GluA4).